SQ 65,396: a non-sedative anxiolytic?
D000249:Adenosine Monophosphate; D000328:Adult; D001007:Anxiety; D002082:Butylamines / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use; D014149:Tranquilizing Agents / Q000009:adverse effects / Q000627:therapeutic use*
D002082:Butylamines; D010726:Phosphodiesterase Inhibitors; D010919:Placebos; D011720:Pyrazoles; D011725:Pyridines; D014149:Tranquilizing Agents; D000249:Adenosine Monophosphate